Lexaria Historical Income Statement

Stocks . USA . 
Stock . Lexaria Bioscience Corp
LEXXW Stock  USD 0.75  0.12  19.05%   
Historical analysis of Lexaria Bioscience income statement accounts such as Total Operating Expenses of 8.1 M can show how well Lexaria Bioscience Corp performed in making a profits. Evaluating Lexaria Bioscience income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lexaria Bioscience's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Lexaria Bioscience Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lexaria Bioscience Corp is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Lexaria Income Statement Analysis

Lexaria Bioscience Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lexaria Bioscience shareholders. The income statement also shows Lexaria investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Lexaria Bioscience Income Statement Chart

At this time, Lexaria Bioscience's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to about 125.2 K in 2024, despite the fact that EBIT is likely to grow to (5.6 M).
Other Operating Expenses  Total Operating Expenses  Cost Of Revenue  
Add Fundamental

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lexaria Bioscience Corp. It is also known as Lexaria Bioscience overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Cost Of Revenue

Cost of Revenue is found on Lexaria Bioscience Corp income statement and represents the costs associated with goods and services Lexaria Bioscience provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most accounts from Lexaria Bioscience's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lexaria Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
At this time, Lexaria Bioscience's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to about 125.2 K in 2024, despite the fact that EBIT is likely to grow to (5.6 M).
 2021 2023 2024 (projected)
Other Operating Expenses7.6M7.8M8.2M
Interest Expense114.3K102.9K125.2K

Lexaria Bioscience income statement Correlations

Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income
Income Tax Expense
Total Revenue
Gross Profit
Cost Of Revenue
Selling General Administrative
Selling And Marketing Expenses
Research Development
Net Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Minority Interest
Depreciation And Amortization
0.680.020.10.110.15-0.040.16-0.050.160.170.670.60.57-0.19-0.440.110.080.00.150.13
Interest Expense
0.68-0.130.290.290.32-0.210.20.030.210.040.890.620.87-0.25-0.630.020.00.140.070.12
Other Operating Expenses
0.02-0.13-0.97-0.97-0.961.0-0.950.0-0.92-0.18-0.20.3-0.510.810.490.790.7-0.950.810.62
Operating Income
0.10.29-0.971.01.0-0.980.970.00.930.230.34-0.20.63-0.88-0.6-0.68-0.580.95-0.79-0.61
Ebit
0.110.29-0.971.01.0-0.980.96-0.030.920.240.34-0.210.64-0.88-0.61-0.68-0.590.94-0.79-0.62
Ebitda
0.150.32-0.961.01.0-0.970.96-0.030.930.240.38-0.180.66-0.88-0.63-0.67-0.590.94-0.78-0.61
Total Operating Expenses
-0.04-0.211.0-0.98-0.98-0.97-0.95-0.01-0.92-0.18-0.290.23-0.580.820.530.780.7-0.950.80.62
Income Before Tax
0.160.2-0.950.970.960.96-0.950.150.990.10.3-0.180.55-0.85-0.57-0.7-0.620.97-0.75-0.53
Total Other Income Expense Net
-0.050.030.00.0-0.03-0.03-0.010.150.29-0.870.190.380.040.12-0.01-0.12-0.140.20.10.29
Net Income
0.160.21-0.920.930.920.93-0.920.990.29-0.060.32-0.110.55-0.8-0.57-0.7-0.630.97-0.69-0.44
Income Tax Expense
0.170.04-0.180.230.240.24-0.180.1-0.87-0.06-0.05-0.320.12-0.41-0.090.080.190.0-0.31-0.54
Total Revenue
0.670.89-0.20.340.340.38-0.290.30.190.32-0.050.790.92-0.21-0.49-0.19-0.20.23-0.18-0.05
Gross Profit
0.60.620.3-0.2-0.21-0.180.23-0.180.38-0.11-0.320.790.490.33-0.040.060.01-0.210.220.33
Cost Of Revenue
0.570.87-0.510.630.640.66-0.580.550.040.550.120.920.49-0.49-0.66-0.36-0.350.49-0.4-0.31
Selling General Administrative
-0.19-0.250.81-0.88-0.88-0.880.82-0.850.12-0.8-0.41-0.210.33-0.490.630.330.2-0.810.610.6
Selling And Marketing Expenses
-0.44-0.630.49-0.6-0.61-0.630.53-0.57-0.01-0.57-0.09-0.49-0.04-0.660.630.080.09-0.470.180.15
Research Development
0.110.020.79-0.68-0.68-0.670.78-0.7-0.12-0.70.08-0.190.06-0.360.330.080.97-0.750.760.38
Net Interest Income
0.080.00.7-0.58-0.59-0.590.7-0.62-0.14-0.630.19-0.20.01-0.350.20.090.97-0.660.650.26
Net Income From Continuing Ops
0.00.14-0.950.950.940.94-0.950.970.20.970.00.23-0.210.49-0.81-0.47-0.75-0.66-0.74-0.51
Reconciled Depreciation
0.150.070.81-0.79-0.79-0.780.8-0.750.1-0.69-0.31-0.180.22-0.40.610.180.760.65-0.740.79
Minority Interest
0.130.120.62-0.61-0.62-0.610.62-0.530.29-0.44-0.54-0.050.33-0.310.60.150.380.26-0.510.79
Click cells to compare fundamentals

Lexaria Bioscience Account Relationship Matchups

High Positive Relationship

Total Operating Expenses
+ 1.0
Other Operating Expenses
Ebit
+ 1.0
Operating Income
Ebitda
+ 1.0
Operating Income
Ebitda
+ 1.0
Ebit
Net Income
+ 0.99
Income Before Tax
Income Before Tax
+ 0.97
Operating Income

High Negative Relationship

Total Operating Expenses
- 0.98
Ebit
Total Operating Expenses
- 0.98
Operating Income
Total Operating Expenses
- 0.97
Ebitda
Ebit
- 0.97
Other Operating Expenses
Operating Income
- 0.97
Other Operating Expenses
Ebitda
- 0.96
Other Operating Expenses

Lexaria Bioscience income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization146.1K147.6K146.9K145.4K130.9K132.7K
Interest Expense59.0K150.6K137.1K114.3K102.9K125.2K
Other Operating Expenses4.4M6.4M7.6M6.8M7.8M8.2M
Operating Income(3.9M)(5.7M)(7.4M)(6.5M)(5.9M)(5.6M)
Ebit(4.1M)(5.7M)(6.7M)(6.5M)(5.9M)(5.6M)
Ebitda(4.0M)(5.6M)(6.5M)(6.4M)(5.7M)(5.5M)
Total Operating Expenses4.3M6.2M7.6M6.7M7.7M8.1M
Income Before Tax(4.1M)(4.2M)(7.4M)(6.7M)(6.0M)(5.7M)
Total Other Income Expense Net(192.7K)1.5M(764.6K)(178.5K)(205.3K)(195.0K)
Net Income(4.0M)(2.5M)(7.3M)(6.7M)(6.0M)(5.7M)
Income Tax Expense(54.3K)(1.7M)(114.3K)130.9K117.8K123.7K
Total Revenue384.5K722.7K255.4K226.2K203.6K400.4K
Gross Profit285.2K547.4K183.6K194.7K223.9K212.9K
Cost Of Revenue99.4K175.3K71.8K31.5K28.4K26.9K
Selling General Administrative3.6M5.0M5.7M3.1M3.5M2.4M
Research Development387.1K1.3M1.8M3.7M4.2M4.4M
Net Income From Continuing Ops(4.1M)(4.2M)(7.4M)(6.7M)(6.0M)(6.3M)
Reconciled Depreciation112.8K147.6K141.3K145.4K167.2K96.1K
Minority Interest150.6K159.1K114.3K47.6K54.8K99.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY